NCT05306210Completed
Forxiga CKD Japan Post-Marketing Surveillance (PMS)
Forxiga Tablets 5mg, 10mgGeneral Drug Use-Results Study n in Chronic Kidney Disease (CKD) Patients
Source: ClinicalTrials.gov · Last updated 9 Oct 2025
Brief summary (registry, in English)
To capture safety when Forxige is administrated to CKD patients in the real world setting
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1029 (actual)
- First submitted
- 23 Mar 2022
- Start date
- 12 Apr 2022
- Primary completion date
- 8 Oct 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Chronic kidney disease
- NCT number
- NCT05306210
What you commit to
- Study type: Observational
- Participants enrolled: 1029
- From 12 Apr 2022 to the primary completion date, 8 Oct 2024
- 46 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients with CKD except for dialysis and/or renal failure chronic
Sex: All · Does not accept healthy volunteers
Sites (46)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.